Drugs / IMA-026
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00725582 | Sep 2008 → Jun 2009 | asthma | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | Missed primary |
| Phase 1 | NCT00528099 | Oct 2007 → Nov 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00517348 | Sep 2007 → Jul 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMA-026 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00517348 ↗ |
| Route | Intravenous | “IMA-026 administered subcutaneously (SC) or intravenously (IV) in healthy adults.” NCT00517348 ↗ |
| Route | Subcutaneous | “IMA-026 administered subcutaneously (SC) or intravenously (IV) in healthy adults.” NCT00517348 ↗ |